

# Svetlana Gelperina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7714102/publications.pdf>

Version: 2024-02-01

46  
papers

5,199  
citations

172457

29  
h-index

233421

45  
g-index

47  
all docs

47  
docs citations

47  
times ranked

6179  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative analysis of palladacycle-tagged PLGA nanoparticle biodistribution in rat organs by means of atomic absorption spectrometry and inductively coupled plasma mass spectrometry. <i>Journal of Analytical Atomic Spectrometry</i> , 2021, 36, 2423-2430.	3.0	5
2	Comparative morphological and biochemical characteristics of the toxic effects of doxorubicin and nanosomal PLGA-doxorubicin form in the experimental glioblastoma treatment. <i>Clinical and Experimental Morphology</i> , 2021, 10, 58-65.	0.2	1
3	Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin. <i>Molecules</i> , 2021, 26, 831.	3.8	17
4	Fluorescently Labeled PLGA Nanoparticles for Visualization In Vitro and In Vivo: The Importance of Dye Properties. <i>Pharmaceutics</i> , 2021, 13, 1145.	4.5	12
5	Exploring the systemic delivery of a poorly water-soluble model drug to the retina using PLGA nanoparticles. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 164, 105905.	4.0	1
6	Injectable drug delivery systems of doxorubicin revisited: In vitro-in vivo relationships using human clinical data. <i>International Journal of Pharmaceutics</i> , 2021, 608, 121073.	5.2	15
7	Release kinetics of fluorescent dyes from PLGA nanoparticles in retinal blood vessels: In vivo monitoring and ex vivo localization. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 150, 131-142.	4.3	17
8	How subtle differences in polymer molecular weight affect doxorubicin-loaded PLGA nanoparticles degradation and drug release. <i>Journal of Microencapsulation</i> , 2020, 37, 283-295.	2.8	23
9	Optimization of Methods for Determination of the Encapsulation Efficiency of Doxorubicin in the Nanoparticles Based on Poly(lactic-co-glycolic acid) (PLGA). <i>Drug Development and Registration</i> , 2020, 9, 113-118.	0.6	0
10	CYTOTOXICITY AND HEMOCOMPATIBILITY OF DOXORUBICIN-LOADED PLGA NANOPARTICLES. , 2020, 19, 71-80.	0.3	0
11	Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: Towards the pharmaceutical development. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118733.	5.2	74
12	The blood-brain barrier and beyond: Nano-based neuropharmacology and the role of extracellular matrix. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 17, 359-379.	3.3	41
13	Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma. <i>International Journal of Pharmaceutics</i> , 2019, 554, 161-178.	5.2	52
14	Nanoparticle-based delivery of carbamazepine: A promising approach for the treatment of refractory epilepsy. <i>International Journal of Pharmaceutics</i> , 2018, 547, 10-23.	5.2	31
15	Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A. <i>Journal of Controlled Release</i> , 2017, 253, 1-10.	9.9	29
16	Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells. <i>International Journal of Pharmaceutics</i> , 2017, 524, 77-90.	5.2	122
17	A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13537-e13537.	1.6	13
18	Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging. <i>Journal of Controlled Release</i> , 2015, 199, 63-71.	9.9	29

#	ARTICLE	IF	CITATIONS
19	Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 87, 132-141.	4.3	33
20	Transferrin-Coated Gadolinium Nanoparticles as MRI Contrast Agent. <i>Molecular Imaging and Biology</i> , 2013, 15, 148-154.	2.6	48
21	Adsorption of plasma proteins on uncoated PLGA nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 53-60.	4.3	75
22	Contrast Enhancement of the Brain by Folate-Conjugated Gadolinium-Diethylenetriaminepentaacetic Acid-Human Serum Albumin Nanoparticles by Magnetic Resonance Imaging. <i>Molecular Imaging</i> , 2012, 11, 7290.2011.00047.	1.4	8
23	Transport of drugs across the blood-brain barrier by nanoparticles. <i>Journal of Controlled Release</i> , 2012, 161, 264-273.	9.9	584
24	Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. <i>Journal of Controlled Release</i> , 2011, 154, 103-107.	9.9	91
25	Efficient Chemotherapy of Rat Glioblastoma Using Doxorubicin-Loaded PLGA Nanoparticles with Different Stabilizers. <i>PLoS ONE</i> , 2011, 6, e19121.	2.5	138
26	Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 74, 157-163.	4.3	260
27	Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. <i>Journal of Drug Targeting</i> , 2009, 17, 564-574.	4.4	198
28	Encapsulation of Water-Insoluble Drugs in Poly(butyl cyanoacrylate) Nanoparticles. <i>Journal of Nanoscience and Nanotechnology</i> , 2009, 9, 5091-5098.	0.9	16
29	Increased Numbers of Injections of Doxorubicin Bound to Nanoparticles Lead to Enhanced Efficacy Against Rat Glioblastoma 101/8. <i>Journal of Nanoneuroscience</i> , 2009, 1, 144-151.	0.5	10
30	Radiation sterilisation of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles. <i>International Journal of Pharmaceutics</i> , 2008, 356, 325-332.	5.2	40
31	Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. <i>Toxicology Letters</i> , 2008, 178, 9-19.	0.8	42
32	Use of Nanoparticles for Cerebral Cancer. <i>Tumori</i> , 2008, 94, 271-277.	1.1	111
33	Use of nanoparticles for cerebral cancer. <i>Tumori</i> , 2008, 94, 271-7.	1.1	34
34	Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity. <i>International Journal of Pharmaceutics</i> , 2007, 337, 346-356.	5.2	66
35	Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular <i>Mycobacterium tuberculosis</i> . <i>International Journal of Pharmaceutics</i> , 2007, 345, 154-162.	5.2	114
36	Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. <i>Journal of Controlled Release</i> , 2007, 118, 54-58.	9.9	247

#	ARTICLE	IF	CITATIONS
37	Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 117, 51-58.	9.9	287
38	Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. Journal of Drug Targeting, 2006, 14, 614-622.	4.4	47
39	Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. Journal of Drug Targeting, 2006, 14, 97-105.	4.4	122
40	Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.8	92
41	Brain Delivery by Nanoparticles. Drugs and the Pharmaceutical Sciences, 2006, , .	0.1	2
42	The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1487-1490.	5.6	579
43	Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. International Journal of Cancer, 2004, 109, 759-767.	5.1	414
44	Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharmaceutical Research, 2003, 20, 409-416.	3.5	404
45	Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicology Letters, 2002, 126, 131-141.	0.8	186
46	Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceutical Research, 1999, 16, 1564-1569.	3.5	468